US 11,795,211 B2
Rapid elicitation of broadly neutralizing antibodies to HIV Env
Devin Sok, New York, NY (US); Dennis R. Burton, La Jolla, CA (US); Vaughn V. Smider, La Jolla, CA (US); Ian Wilson, La Jolla, CA (US); Michael Criscitiello, College Station, TX (US); and Waithaka Mwangi, College Station, TX (US)
Assigned to International AIDS Vaccine Initiative, New York, NY (US); The Scripps Research Institute, La Jolla, CA (US); and THE TEXAS A&M UNIVERSITY SYSTEM, College Station, TX (US)
Appl. No. 16/630,768
Filed by International AIDS Vaccine Initiative, New York, NY (US); The Scripps Research Institute, La Jolla, CA (US); and The Texas A&M University System, College Station, TX (US)
PCT Filed Jul. 12, 2018, PCT No. PCT/US2018/041729
§ 371(c)(1), (2) Date Jan. 13, 2020,
PCT Pub. No. WO2019/014405, PCT Pub. Date Jan. 17, 2019.
Claims priority of provisional application 62/532,766, filed on Jul. 14, 2017.
Claims priority of provisional application 62/534,501, filed on Jul. 19, 2017.
Prior Publication US 2020/0165324 A1, May 28, 2020
Int. Cl. C07K 16/00 (2006.01); C07K 16/10 (2006.01); C07K 14/16 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/1063 (2013.01) [C07K 14/162 (2013.01); A61K 38/00 (2013.01); C07K 2317/10 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/31 (2013.01)] 13 Claims
 
1. An isolated monoclonal antibody that specifically binds to HIV Env and comprises a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3, wherein the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 3, and wherein the VH CDR1, VH CDR2, VL CDR1, VL CDR2, and VL CDR3 are from
a) NC-Cow1, NC-Cow7, NC-Cow8, NC-Cow9, or NC-Cow10; or
b) germline reverted NC-Cow1.